CR20220085A - Compuestos de pirazol, formulaciones de los mismos y un método para usar los compuestos y/o formulaciones - Google Patents

Compuestos de pirazol, formulaciones de los mismos y un método para usar los compuestos y/o formulaciones

Info

Publication number
CR20220085A
CR20220085A CR20220085A CR20220085A CR20220085A CR 20220085 A CR20220085 A CR 20220085A CR 20220085 A CR20220085 A CR 20220085A CR 20220085 A CR20220085 A CR 20220085A CR 20220085 A CR20220085 A CR 20220085A
Authority
CR
Costa Rica
Prior art keywords
formulations
compounds
composition
compound
disclosed
Prior art date
Application number
CR20220085A
Other languages
English (en)
Inventor
Vanessa Taylor
Dazhong Fan
Matt Duan
Somasekhar Bhamidipati
Yan Chen
Simon Shaw
Zhushou Luo
Lu Chuo
Ihab Darwish
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of CR20220085A publication Critical patent/CR20220085A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se desvelan realizaciones de un compuesto de pirazol de acuerdo con la fórmula (I). Fórmula I También se desvelan composiciones que comprenden el compuesto, y un método para preparar la composición. La composición puede comprender un vehículo, tal como un polímero<em> y/o la composición puede ser una formulación secada por pulverización. También se desvela un método para usar el compuesto y/o </em>composición<em>. El compuesto y/o </em>composición <em>pueden ser útiles </em>para inhibir una proteína IRAK y/o para mejorar, tratar y/o prevenir una enfermedad o afección asociada a IRAK en un sujeto.
CR20220085A 2019-08-30 2020-08-28 Compuestos de pirazol, formulaciones de los mismos y un método para usar los compuestos y/o formulaciones CR20220085A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962894547P 2019-08-30 2019-08-30
PCT/US2020/048528 WO2021041898A1 (en) 2019-08-30 2020-08-28 Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations

Publications (1)

Publication Number Publication Date
CR20220085A true CR20220085A (es) 2022-04-19

Family

ID=72473975

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220085A CR20220085A (es) 2019-08-30 2020-08-28 Compuestos de pirazol, formulaciones de los mismos y un método para usar los compuestos y/o formulaciones

Country Status (18)

Country Link
US (3) US11370787B2 (es)
EP (1) EP4003990A1 (es)
JP (1) JP2022545542A (es)
KR (1) KR20220054626A (es)
CN (1) CN114364674A (es)
AR (1) AR119857A1 (es)
AU (1) AU2020335903A1 (es)
BR (1) BR112022003564A2 (es)
CA (1) CA3152264A1 (es)
CO (1) CO2022002993A2 (es)
CR (1) CR20220085A (es)
EC (1) ECSP22014379A (es)
IL (1) IL290882A (es)
JO (1) JOP20220050A1 (es)
MX (1) MX2022002292A (es)
PE (1) PE20220970A1 (es)
TW (1) TW202122393A (es)
WO (1) WO2021041898A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11370787B2 (en) * 2019-08-30 2022-06-28 Rigel Pharmaceuticals, Inc. Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
WO2022187303A1 (en) * 2021-03-03 2022-09-09 Rigel Pharmaceuticals, Inc. A method for treating a disease or condition using a pyrazole compound or formulation thereof
US20230303555A1 (en) * 2022-03-23 2023-09-28 Rigel Pharmaceuticals, Inc. Pyrimid-2-yl-pyrazole compounds as irak inhibitors

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
CA2031376A1 (en) 1989-12-04 1991-06-05 Bahram Farhadieh Single layer transdermal drug administration system
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
JPH07502219A (ja) 1991-12-18 1995-03-09 ミネソタ　マイニング　アンド　マニュファクチャリング　カンパニー 多重層型バリアー構造体
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH &amp; CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
WO2004037248A2 (en) 2002-10-24 2004-05-06 Carex Sa Modulation of peroxisome proliferator activated receptors activity
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
WO2006070202A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives having kinase modulating activity
US20100160324A1 (en) 2004-12-30 2010-06-24 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
PL2206707T3 (pl) 2007-10-24 2015-01-30 Astellas Pharma Inc Związek azolokarboksamidowy lub jego sól
EP2070925A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel
WO2010121243A1 (en) 2009-04-17 2010-10-21 University Of Arizona Compounds, pharmaceutical compositions and methods of use of 2-aryl pyridylazoles
EP2243481A1 (en) 2009-04-24 2010-10-27 PamGene B.V. Irak kinase family as novel drug target for Alzheimer
JP2012254939A (ja) 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物
MA34234B1 (fr) 2010-04-07 2013-05-02 Hoffmann La Roche Composes pyrazol-4-yl-heterocyclyle-carboxamide et leurs procedes d'utilisation
CN108864151A (zh) 2010-11-19 2018-11-23 利亘制药公司 杂环胺及其用途
WO2012072685A1 (en) 2010-12-02 2012-06-07 Katholieke Universiteit Leuven, K.U.Leuven R&D Irak-related interventions and diagnosis
PL2655357T3 (pl) 2010-12-20 2016-12-30 Pochodne triazolowe indazolilowe jako inhibitory irak
US8703941B2 (en) 2011-01-10 2014-04-22 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
EP2674423A4 (en) 2011-02-09 2014-07-30 Nissan Chemical Ind Ltd PYRAZONE DERIVATIVE AND PESTICIDES
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
SG2014012579A (en) 2011-09-27 2014-04-28 Hoffmann La Roche Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
AU2013207972B2 (en) 2012-01-10 2017-06-15 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
US9328106B2 (en) 2012-09-26 2016-05-03 Genentech, Inc. Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
EP2903613B1 (en) 2012-10-08 2017-11-22 Merck Sharp & Dohme Corp. Pyrazole derivatives useful as inhibitors of irak4 activity
LT2953952T (lt) 2013-02-07 2017-08-25 Merck Patent Gmbh Makrocikliniai piridazinono dariniai
WO2014121931A1 (en) 2013-02-07 2014-08-14 Merck Patent Gmbh Pyridazinone-amides derivatives
CA2933107C (en) 2014-01-09 2022-06-21 Merck Patent Gmbh Pyrimidine pyrazolyl derivatives and their use as irak inhibitors
ES2772133T3 (es) 2014-11-20 2020-07-07 Merck Patent Gmbh Compuestos heteroarilo como inhibidores de IRAK y sus usos
BR112017022349B1 (pt) * 2015-04-22 2023-11-07 Rigel Pharmaceuticals, Inc Composto, composição o compreendendo, seus usos, e, método
CA3041587A1 (en) * 2016-10-26 2018-05-17 Rigel Pharmaceuticals, Inc. Oxazole derivatives for use as irak inhibitors and method for their preparation
US11370787B2 (en) * 2019-08-30 2022-06-28 Rigel Pharmaceuticals, Inc. Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations

Also Published As

Publication number Publication date
US20210061798A1 (en) 2021-03-04
US20230399326A1 (en) 2023-12-14
PE20220970A1 (es) 2022-06-10
IL290882A (en) 2022-04-01
AR119857A1 (es) 2022-01-19
JOP20220050A1 (ar) 2023-01-30
US11370787B2 (en) 2022-06-28
KR20220054626A (ko) 2022-05-03
TW202122393A (zh) 2021-06-16
CA3152264A1 (en) 2021-03-04
WO2021041898A1 (en) 2021-03-04
US20220306620A1 (en) 2022-09-29
CN114364674A (zh) 2022-04-15
CO2022002993A2 (es) 2022-04-19
AU2020335903A1 (en) 2022-03-24
EP4003990A1 (en) 2022-06-01
BR112022003564A2 (pt) 2022-05-17
ECSP22014379A (es) 2022-05-31
JP2022545542A (ja) 2022-10-27
MX2022002292A (es) 2022-06-02

Similar Documents

Publication Publication Date Title
ECSP22014379A (es) Compuestos de pirazol, formulaciones de los mismos y un método para usar los compuestos y/o formulaciones
CL2020002511A1 (es) Compuestos heterocíclicos como inmunomoduladores.
MX2021004707A (es) Nuevos compuestos antihelminticos.
PE20171517A1 (es) Compuestos y composiciones de alfa-cinamida como inhibidores de hdac 8
CL2017002207A1 (es) Inhibidores del factor beta de crecimiento de transformación (tgf-beta)
CL2019000986A1 (es) 1,3 di sustituto ciclobutano o derivados de azetidina como inhibidores de prostaglandina d sintasa hematopoyética(h-pgds).
CO6361922A2 (es) Inhibidores del virus de la hepatitis c
ECSP17026210A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
ECSP066997A (es) Derivados de pirimidina para tratar el crecimiento celular anómalo
UY37764A (es) Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds)
MX2016012937A (es) Compuestos de azol amido-sutituidos como inhibidores de tnks1 y/o tnks2.
BR112021014640A8 (pt) Sais de sulcardina
BR112022011309A2 (pt) Compostos de trisamida e composições compreendendo os mesmos
BR112022011194A2 (pt) Compostos de trisamida e composições compreendendo os mesmos
BR112021002565A8 (pt) Composto, sal farmaceuticamente aceitável, tautômero ou estereoisômero do mesmo, composição farmacêutica, processo para a síntese e uso do dito composto
MX2020004981A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
BR112019003281A2 (pt) composição farmacêutica e métodos de usos
BR112017028185A2 (pt) composições farmacêuticas sólidas para tratar hcv
BR112022004777A2 (pt) Composição de micela de estimulação imunológica
BR112018000982A2 (pt) composições farmacêuticas sólidas para tratar hcv
BR112022002769A2 (pt) Composto, composição farmacêutica, e, método para tratar ou prevenir uma condição
BR112021023282A2 (pt) Composto, método para preparar um composto de fórmula química 1, e, composição farmacêutica
BR112021020222A2 (pt) Composições farmacêuticas sólidas para tratar hcv
BR112023008166A2 (pt) Composições de lnp compreendendo rna e métodos para preparar, armazenar e usar as mesmas